Nasacort OTC Dual Allergy/Decongestion Relief Could Be Marketing Edge
This article was originally published in The Tan Sheet
Executive Summary
Sanofi’s Nasacort likely can carve out sales in the crowded nonprescription allergy market with promises of allergy relief plus decongestion in a product available OTC, unlike most competitors including Claritin D, Zyrtec D and Allegra D, which contain pseudoephedrine and are sold behind-the-counter.
You may also be interested in...
‘Emotional’ NDACs Stymie OTC Switches – Former Chairman Wood
OTC industry stakeholders must prepare better for FDA Nonprescription Drug Advisory Committee meetings and argue against members’ “emotional” objections to switches based on retail price or loss of doctor-patient visits, says former NDAC chair Alistair Wood.
‘Emotional’ NDACs Stymie OTC Switches – Former Chairman Wood
OTC industry stakeholders must prepare better for FDA Nonprescription Drug Advisory Committee meetings and argue against members’ “emotional” objections to switches based on retail price or loss of doctor-patient visits, says former NDAC chair Alistair Wood.
‘Emotional’ NDACs Stymie OTC Switches – Former Chairman Wood
OTC industry stakeholders must prepare better for FDA Nonprescription Drug Advisory Committee meetings and argue against members’ “emotional” objections to switches based on retail price or loss of doctor-patient visits, says former NDAC chair Alistair Wood.